2.13

7.39% -0.17

Bioxcel Therapeutics Inc (BTAI)

Overview News Price History Option Chain Financials Why BTAI Down? Discussions Forecast

Bioxcel Therapeutics Inc stock is traded at $2.13, with a volume of 122.71K. It is down -7.39% in the last 24 hours and up +494.97% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Previous Close:

$2.30

Open:

$2.27

24h Volume:

122.71K

Relative Volume:

0.07

Market Cap:

$6.61M

Revenue:

$1.38M

Net Income/Loss:

$-179.05M

P/E Ratio:

-0.3469

EPS:

-6.14

Net Cash Flow:

$-155.03M

1W Performance:

-7.79%

1M Performance:

+494.97%

6M Performance:

+213.01%

1Y Performance:

-32.38%

1-Day Range:

$2.10

$2.30

1-Week Range:

$2.10

$2.60

52-Week Range:

$0.16

$3.50

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name

Bioxcel Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

203-643-8060

Address

555 LONG WHARF DRIVE, NEW HAVEN, CT

Employee

Twitter

@bioxcel_tx

Next Earnings Date

2024-11-12

Latest SEC Filings

BTAI's Discussions on Twitter

Compare BTAI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BTAI Bioxcel Therapeutics Inc	2.13	6.61M	1.38M	-179.05M	-155.03M	-6.14
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-24	Downgrade	UBS	Buy → Neutral
Aug-15-23	Downgrade	Mizuho	Buy → Neutral
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold
Dec-01-22	Upgrade	Goldman	Sell → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-06-22	Reiterated	BofA Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-09-21	Initiated	Berenberg	Buy
Feb-01-21	Initiated	UBS	Buy
Oct-30-20	Initiated	Goldman	Buy
Sep-02-20	Initiated	Jefferies	Buy
Aug-17-20	Reiterated	H.C. Wainwright	Buy
Jul-08-20	Reiterated	H.C. Wainwright	Buy
Jun-04-20	Initiated	Guggenheim	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-12-19	Initiated	SunTrust	Buy

View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

Feb 21, 2025

BTAI stock plunges to 52-week low of $2.16 amid market challenges - Investing.com Nigeria

Feb 21, 2025

Feb 20, 2025

A significant driver of top-line growth: BioXcel Therapeutics Inc (BTAI) - SETE News

Feb 10, 2025

You Should Look At The Stock Forecast For BioXcel Therapeutics Inc (NASDAQ: BTAI). - Marketing Sentinel

Feb 10, 2025